SWI Initiates Coverage on Immune Pharmaceuticals (IMNP)
Leading Product Candidate Enters Phase II Clinical Trials
Los Angeles, December 21, 2105. - StockWatchIndex (SWI) today announced that it has initiated coverage on Immune Pharmaceuticals Inc. (IMNP) as a new addition to its Biotech WatchIndex, representing a unique buying opportunity.
Immune Pharmaceuticals Inc. (IMNP) is a clinical stage development company developing novel therapies for the treatment of immune-inflammatory diseases and cancer. Immune Pharmaceuticals is implementing a new and highly personalized approach to disease treatment and developing novel and highly targeted antibody therapeutics to improve the lives of patients.
FDA Approval and Phase II Clinical Trials
In 2015 , Immune made important progress with its lead drug candidate, Bertilimumab, receiving clearance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application. This approval allows the company to include U.S. patients in its Phase II clinical trial in bullous pemphigoid, an orphan auto-immune disease of the skin. Immune is also starting to enroll patients in the Phase II clinical trial for moderate to severe ulcerative colitis, a serious immuno-inflammatory condition of the gastro-intestinal tract. Other indications planned for Bertilimumab development include Crohn’s disease, severe asthma and liver diseases (NASH). The company recently expanded its portfolio in immuno-dermatology, topical Nano formulated Cyclosporine A (CsA) for the treatment of psoriasis and atopic dermatitis.
The Company is also currently evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology with chemo therapeutics in order to enhance safety and efficacy profiles, by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline includes proprietary antibodies and clinical-stage small molecules that have been shown activity in a variety of solid tumors.
Completing Clinical Trials
The Company secured sufficient financing for the timely execution of the development plan for its lead drug candidate Bertilimumab through both Phase II clinical trials and has relocated its corporate headquarters to New York City at the Alexandria Center for Life Sciences, the heart of the NYC medical and biotech corridor. Immune has engaged a new leadership team with a proven track record of successful execution in both pharma and fast growth biotech companies with former positions at Teva, Aposense, CV Therapeutics, Novartis and Merck, among others. The Company has also committed to further strengthening its Board of Directors with the addition of new members with successful leadership experience at public biotech companies.
Unique Buying Opportunity
SWI believes that the advancement in Immune's product development, the FDA's approval for the Investigational New Drug (IND) application, the company's plans for the expansion of its clinical trial centers and the engagement of a new, highly experienced management team should result in reaching the mile stones that Immune has set for itself for 2016 and that investors expect.
While the shares are currently trading only slightly above the low end of the stock's 52 week range, the company has secured sufficient funding for the completion of its Phase II clinical trials. The company has moved its U.S. headquarters to the heart of the Bio Tech industry in New York and revamped its management with highly experienced members recruited from leading biotech firms in the U.S.. We believe that the successful execution of these actions reflects the commitment and capability of top management, lead by the CEO Dr. Daniel Teper, and represents a unique buying opportunity for the stock. We will follow up with a detailed research report. In the meanwhile watch the Immune Pharmaceuticals video on our partner site www.smallcapnation.com.
Immune Pharmaceutical Video
on Small Cap Nation